SNO 2021: In Recurrent GBM, Autologous Adoptive Immune Cell Therapy Elicits a Durable Response
The therapy may benefit patients with high immune response in their tumor microenvironments.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.